JS207 Combination Therapy in Triple-negative Breast Cancer
Status:
RECRUITING
Trial end date:
2029-03-22
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.